Navigation Links
Patients Can Now Visit Their Dentist for Treatment and Monitoring of Sleep Apnea

MELVILLE, N.Y., Nov. 28, 2011 /PRNewswire/ -- Henry Schein, Inc. (Nasdaq: HSIC), the largest provider of health care products and services to office-based practitioners, today announced the launch of its Sleep Complete™ program, a new integrated comprehensive solution that provides all of the information and products necessary for the successful implementation of dental sleep medicine into the dental practice.  Henry Schein Dental's Sleep Complete program was developed in collaboration with Nierman Practice Management, Modern Dental Laboratory USA and Itamar Medical.

Henry Schein Dental's Sleep Complete program provides tools to address all of the key components of dental sleep medicine:  education, treatment, reimbursement and monitoring. The Sleep Complete package includes the Dental Writer™ Diagnostic Report Writer and Medical Billing Software for Dentistry through Nierman Practice Management.  This specialty software simplifies the billing and reimbursement process for dentists on procedures that require reimbursement from the patients' medical insurance and provides the tools needed to easily submit reimbursement paperwork at the click of a button.  Additionally, as part of the Sleep Complete package, Henry Schein Dental is offering dentists registration to the Nierman Practice Management two-day "Successful Implementation of Dental Sleep Medicine" seminars featuring Dr. John H. Tucker, D.M.D., Diplomate ABDSM, Diplomate ICOI.  These two-day live educational courses offered around the country as well as one-hour webinars provide dentists with a comprehensive overview of sleep disorders and guide them in successfully incorporating dental sleep medicine into their practice. 

The Sleep Complete package also includes the oral appliance starter kit from Modern Dental Laboratory USA that consists of pre-paid vouchers for The Moses™, the EMA® First Step and EMA® Custom oral appliances as well as marketing materials and other useful tools for the dentist to incorporate this therapy solution into their practice.  This selected range of oral appliances offer options suited to all types of patients. These appliances are all FDA cleared for the treatment of snoring and mild to moderate sleep apnea, or for patients that cannot tolerate CPAP (Continuous Positive Air Pressure).

The final component of the Sleep Complete package is the WatchPAT™ testing device provided through Itamar Medical.  WatchPAT is a user-friendly, non-invasive, portable sleep testing device that gathers data related to the patient's sleep tendencies that can be interpreted by a sleep physician and used by the dentist to titrate the oral appliance being used for the treatment of obstructive sleep apnea.  Dentists utilize the WatchPAT portable sleep monitoring device in collaboration with the patient's physician. 

"Sleep apnea is a serious health problem, and dental sleep medicine presents a very promising practice extension opportunity for dentists," said Tim Sullivan, President of Henry Schein Dental.  "Our Sleep Complete program provides all of the key tools and guidance necessary to help dentists easily navigate the intricacies of treatment, reimbursement and monitoring, and makes it simple for our dentist customers to successfully incorporate dental sleep medicine into their practices."

Sleep apnea, which occurs when the tongue and soft tissues fall back into the throat and block the airway during sleep, is a very serious health condition.  According to the American Academy of Sleep Medicine, approximately one-half of people who snore loudly have obstructive sleep apnea, which can contribute to an increased risk for high blood pressure, heart attack, stroke, diabetes, depression, memory and concentration problems, obesity, excessive daytime sleepiness, and driving accidents.  The American Academy of Sleep Medicine also notes that while an estimated 18 million Americans suffer from sleep apnea, 80-90 percent remain undiagnosed. 

The Sleep Complete package will be offered to dentists through a bundled financing package through Henry Schein Financial Services, significantly lowering the financial barrier to entry that often faces dentists interested in incorporating sleep medicine into their practice.

About Henry Schein, Inc.
Henry Schein, Inc. (NASDAQ: HSIC), the largest provider of health care products and services to office-based practitioners, is a Fortune 500® company and a member of the NASDAQ 100® Index.  The Company is recognized for its excellent customer service and highly competitive prices.  Henry Schein's five businesses – Dental, Medical, Animal Health, International and Technology – serve more than 700,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health practices, as well as government and other institutions.  The Company operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 90,000 national and Henry Schein private-brand products in stock, as well as more than 100,000 additional products available as special-order items.  Henry Schein also provides exclusive, innovative technology offerings for dental, medical and veterinary professionals, including value-added practice management software and electronic health record solutions.

Headquartered in Melville, N.Y., Henry Schein employs more than 14,000 people and has operations or affiliates in 25 countries.  The Company's net sales reached a record $7.5 billion in 2010.  For more information, visit the Henry Schein Web site at

In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the SEC and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: recently enacted healthcare legislation; effects of a highly competitive market; changes in the healthcare industry; changes in regulatory requirements; risks from expansion of customer purchasing power and multi-tiered costing structures; risks associated with our international operations; fluctuations in quarterly earnings; our dependence on third parties for the manufacture and supply of our products; transitional challenges associated with acquisitions, including the failure to achieve anticipated synergies; financial risks associated with acquisitions; regulatory and litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment; risks from disruption to our information systems; general economic conditions; decreased customer demand and changes in vendor credit terms; disruptions in financial markets; our dependence upon sales personnel, manufacturers and customers; our dependence on our senior management; possible increases in the cost of shipping our products or other service issues with our third-party shippers; risks from rapid technological change; possible volatility of the market price of our common stock; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.

SOURCE Henry Schein, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. Many Heart Attack Patients Dont Get Best Emergency Treatment
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... Wound Care Market by Type (Dressings, Therapy Devices, Active ... Facility, Out-Patient Facility), and Geography - Global Forecast to ... --> --> The purpose of ... forecast of the global advanced wound care market. It ...
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Surface Marker Testing Market: Supplier Shares, ... their offering.  --> ... the  "2016 Future Horizons and Growth ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast cancers found with ... according to a study published online in the journal Radiology. Researchers said that ... necessitate a change in treatment. , Breast MRI is the most sensitive technique ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional and far-infrared ... traditional and far-infrared saunas. , For traditional saunas, Finnleo is offering ... sauna wood, and Finnleo uses only European Grade A Nordic White Spruce from sustainably ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director ... about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for ... and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would ... OH , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE ... Cleveland, OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli ...
Breaking Medicine News(10 mins):